Locations:
SearchCompany currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines. The research under the new joint development agreement will be led at Cleveland Clinic by Thaddeus Stappenbeck, MD, PhD, Department Chair of Inflammation and Immunity.
Anixa Biosciences, Inc. recently announced a joint development agreement (JDA) with Cleveland Clinic to develop novel vaccines for various cancer types. The focus is on targeting triple negative breast cancer (TNBC) and developing an ovarian cancer vaccine using a novel scientific mechanism. The vaccines aim to immunize against specific "retired" proteins found to be expressed in certain forms of cancer, potentially preventing tumor formation and destroying cancer cells as they arise.
The research under this new JDA will be led at Cleveland Clinic by Thaddeus Stappenbeck, MD, PhD, Department Chair of Inflammation and Immunity, and will include Justin Johnson, PhD, one of the co-inventors of the breast and ovarian cancer vaccines. Anixa Chairman and CEO Dr. Amit Kumar expressed confidence in the potential of the breast cancer vaccine program and the pursuit of additional vaccines and cancer types using the same technology platform.
"We look forward to expanding our relationship with Anixa in this endeavor," said Dr. Stappenbeck. "As we begin the discovery effort to evaluate which cancer types will be best for targeting, we hope to address many intractable cancers, including high incidence malignancies in the lung, colon, and prostate."
Read the full press release via PRNewswire
